original ) (raw )West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph nodes
Anthony Howell
British journal of cancer, 1989
View PDFchevron_right
Symptomatology as an indicator of recurrent or metastatic breast cancer
miguel gonzález oviedo
Cancer, 1979
View PDFchevron_right
Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy
Donna Jeffe
Breast Cancer Research and Treatment, 2013
View PDFchevron_right
A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Locoregional Relapse of Breast Cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
André Robidoux , Irene Wapnir
Clinical Breast Cancer, 2008
View PDFchevron_right
Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy
Francisco Esteva
JNCI: Journal of the National Cancer Institute, 2008
View PDFchevron_right
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy
Jennifer Lei
JAMA oncology, 2015
View PDFchevron_right
Effectiveness of Follow-Up for Breast Cancer Patients
BRAHIM LAKHLIFI
View PDFchevron_right
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation
Michael Goodyear
British journal of cancer, 1992
View PDFchevron_right
Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a Prospective Randomized Trial Evaluating Chemotherapy after Local Therapy for Isolated Locoregional Recurrences of Breast Cancer
André Robidoux , Irene Wapnir
Annals of Surgical Oncology, 2008
View PDFchevron_right
Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trial
Enrique Garcia
European Journal of Cancer, 1992
View PDFchevron_right
Patients with Recurrent Breast Cancer: Does the Primary Axillary Lymph node Status Predict more Aggressive Tumor Progression?
Bernd Gerber
Breast Cancer Research and Treatment, 2003
View PDFchevron_right
The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival
fügen aker
Clinical and Translational Oncology, 2015
View PDFchevron_right
Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: The natural history of an elusive prognosticator
Donna Jeffe
Molecular and Clinical Oncology, 2015
View PDFchevron_right
Neo-adjuvant chemotherapy and the recurrence of breast cancer in a tertiary care rural hospital of West Bengal, India
Sanhita Mukherjee
International Journal of Research in Medical Sciences, 2016
View PDFchevron_right
Breast cancer follow-up in the adjuvant setting
Craig Swainey
Current Oncology Reports, 2008
View PDFchevron_right
Heterogeneity of breast cancer and implications of adjuvant chemotherapy
Rab Razzak
Breast Cancer, 2008
View PDFchevron_right
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial
André Robidoux , Alan Coates , Irene Wapnir
The Lancet Oncology, 2014
View PDFchevron_right
Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes
James Wittliff
Journal of the National Cancer Institute, 2001
View PDFchevron_right
Axillary Recurrence in Sentinel Lymph Node-Negative Breast Cancer Patients in a Tertiary Referral Cancer Centre
ROHIT KUMAR
Indian Journal of Surgery, 2021
View PDFchevron_right
Effect of systemic adjuvant treatment on first sites of breast cancer relapse
Monica Castiglione
The Lancet, 1994
View PDFchevron_right
Prognostic Factors for Breast Cancer Recurrence after Conservative Treatment
Souha Sahraoui
2022
View PDFchevron_right
Lack of Patient Compliance with Adjuvant Therapy Guidelines is an Important Risk Factor for Recurrence in Early Breast Cancer
James Grutsch
2013
View PDFchevron_right
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
Athanasios Athanasiadis , I. Varthalitis
Breast Cancer Research and Treatment, 2010
View PDFchevron_right
Isolated axillary recurrences after conservative treatment of breast cancer
Bernard Asselain
European Journal of Cancer, 1996
View PDFchevron_right
Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy
Noriyuki Katsumata
Breast Diseases: A Year Book Quarterly, 2011
View PDFchevron_right
ARTICLES Prognosis and Treatment of Patients With Breast Tumors of One Centimeter or Less and Negative Axillary Lymph Nodes
James Wittliff
2001
View PDFchevron_right
Adjuvant therapy in breast cancer
Rochelle Strenger
Obstetrics and Gynecology Clinics of North America, 2002
View PDFchevron_right
Evaluation and Reporting of Breast Cancer after Neoadjuvant Chemotherapy
fan fan
The Open Pathology Journal
View PDFchevron_right
Axillary recurrence in breast cancer
David Kingsmore
European Journal of Surgical Oncology (EJSO), 2005
View PDFchevron_right
Patterns of breast cancer relapse
Hugh Carmalt , Elisabeth Elder
European Journal of Surgical Oncology (EJSO), 2006
View PDFchevron_right
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
Philippe J Chollet
british journal of cancer, 2002
View PDFchevron_right
Patterns of relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy followed by surgery and radiotherapy
Gaurav Singh
Journal of Cancer Research and Therapeutics, 2007
View PDFchevron_right
Early distant relapse in ?node-negative? breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour
Peter van Dam
The Journal of Pathology, 2001
View PDFchevron_right
Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of ‘cures’
Pinuccia Valagussa
Breast Cancer Research and Treatment, 1999
View PDFchevron_right
Identifying Good Prognosis Group of Breast Cancer Patients with 1-3 Positive Axillary Nodes for Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF) Chemotherapy
Yung-chang Lin
Japanese Journal of Clinical Oncology, 2005
View PDFchevron_right